NEW YORK, May 30, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
The Antibacterials Market Outlook to 2016
http://www.reportlinker.com/p0535949/The-Antibacterials-Market-Outlook-to-2016.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication
Introduction
This report provides comprehensive coverage of the global antibacterials market, incorporating disease overview, epidemiological analyses of the major indications, market dynamics. Resistors and drivers are examined along with the most promising areas of growth. Current leading antibacterial brands are assessed and five of the market's leading players are profiled.
Features and benefits
* Assess the forecast epidemiology and development of the antibacterials market across the 7MM.
* Analyze the dynamics of the global antibacterials market and understand the impact of key R&D events, market trends, and issues.
* Gain up-to-date competitive intelligence and understand the major issues affecting key pharmaceutical marketers and product development.
* Predict revenues for major currently marketed and pipeline antibacterial products over 2010–16
* Develop strategies for success in the future antibacterial market.
Highlights
Of the competing drug classes in global antibacterials market, cephalosporins occupied the leading position with over 25% share followed by penicillins and fluoroquinolones. However, all these drug classes declined in sales in 2010.
Despite high patient numbers, the cost and complexities coupled with regulatory uncertainties and challenges have shifted the investment focus of pharmaceutical manufacturers from antibacterials to treatments for chronic conditions.
Community acquired pneumonia (CAP) and hospital acquired pneumonia (HAP) infections are attracting research interest. Additionally, the majority of companies developing new antibiotics are targeting cell wall synthesis inhibitors, DNA topoisomerase II inhibitors, ribosomal inhibitors and methionine tRNA ligase inhibitors.
Your Key questions answered
* What are the drivers and resistors of the antibacterials market worldwide?
* What market and pipeline developments are shaping the strategies of leading pharmaceutical companies in the antibacterials market?
* What is the forecast commercial potential of the most promising compounds in clinical development?
* Who were the leading players in the global antibacterials market in 2010?
* How have recent launches from companies such as GSK, Pfizer, J&J, Novartis and Merck & Co. performed?
Executive Summary
Disease overview and epidemiology
Global market analysis
Pipeline analysis
Competitive landscape
About the author
Disclaimer
Disease overview and epidemiology
Summary
Introduction
Bacterial infections
Diagnosis, treatment and management
Epidemiology of bacterial infections
Forecast epidemiology
Global market analysis
Summary
Introduction
Market dynamics
Leading brands dynamics
Resistors of the antibacterial market
Drivers of the antibacterial market
Global antibacterial market sales forecast
Pipeline analysis
Summary
Introduction
Antibacterial pipeline
Key events in antibacterial R&D
Cubist settles patent infringement litigation with Teva over Cubicin
Merck & Co. intends to strengthen antibacterial research through BioRelix
GSK exercises its option with Anacor to commercialize GSK2251052
Zeftera withdrawn following concerns raised by the FDA and the EMA
Durata Therapeutics initiates Phase III trials for dalbavancin
Leading drugs in development
Profiles of key pipeline products
Pipeline forecast to 2016
Competitive landscape
Summary
Introduction
GlaxoSmithKline
Overview
Financial performance
Marketed product portfolio
Research and development
Strategic and growth analysis
Pfizer
Overview
Financial performance
Marketed product portfolio
Research & development
Strategic and growth analysis
Johnson & Johnson
Overview
Financial performance
Marketed product portfolio
Research & development
Strategic and growth analysis
Merck & Co.
Overview
Financial performance
Marketed product portfolio
Research & development
Strategic and growth analysis
Novartis
Overview
Financial performance
Marketed product portfolio
Research & development
Strategic and growth analysis
Appendix
Scope
Market size methodology
Epidemiology
Market forecast
Abbreviations
To order this report:
Drug and Medication Industry: The Antibacterials Market Outlook to 2016
Drug and Medication Business News
More Market Research Report
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas BombourgReportlinkerEmail: [email protected]US: (805)652-2626Intl: +1 805-652-2626
SOURCE Reportlinker
Advertisement
The Antibacterials Market Outlook to 2016
http://www.reportlinker.com/p0535949/The-Antibacterials-Market-Outlook-to-2016.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication
Advertisement
Introduction
This report provides comprehensive coverage of the global antibacterials market, incorporating disease overview, epidemiological analyses of the major indications, market dynamics. Resistors and drivers are examined along with the most promising areas of growth. Current leading antibacterial brands are assessed and five of the market's leading players are profiled.
Features and benefits
* Assess the forecast epidemiology and development of the antibacterials market across the 7MM.
* Analyze the dynamics of the global antibacterials market and understand the impact of key R&D events, market trends, and issues.
* Gain up-to-date competitive intelligence and understand the major issues affecting key pharmaceutical marketers and product development.
* Predict revenues for major currently marketed and pipeline antibacterial products over 2010–16
* Develop strategies for success in the future antibacterial market.
Highlights
Of the competing drug classes in global antibacterials market, cephalosporins occupied the leading position with over 25% share followed by penicillins and fluoroquinolones. However, all these drug classes declined in sales in 2010.
Despite high patient numbers, the cost and complexities coupled with regulatory uncertainties and challenges have shifted the investment focus of pharmaceutical manufacturers from antibacterials to treatments for chronic conditions.
Community acquired pneumonia (CAP) and hospital acquired pneumonia (HAP) infections are attracting research interest. Additionally, the majority of companies developing new antibiotics are targeting cell wall synthesis inhibitors, DNA topoisomerase II inhibitors, ribosomal inhibitors and methionine tRNA ligase inhibitors.
Your Key questions answered
* What are the drivers and resistors of the antibacterials market worldwide?
* What market and pipeline developments are shaping the strategies of leading pharmaceutical companies in the antibacterials market?
* What is the forecast commercial potential of the most promising compounds in clinical development?
* Who were the leading players in the global antibacterials market in 2010?
* How have recent launches from companies such as GSK, Pfizer, J&J, Novartis and Merck & Co. performed?
Executive Summary
Disease overview and epidemiology
Global market analysis
Pipeline analysis
Competitive landscape
About the author
Disclaimer
Disease overview and epidemiology
Summary
Introduction
Bacterial infections
Diagnosis, treatment and management
Epidemiology of bacterial infections
Forecast epidemiology
Global market analysis
Summary
Introduction
Market dynamics
Leading brands dynamics
Resistors of the antibacterial market
Drivers of the antibacterial market
Global antibacterial market sales forecast
Pipeline analysis
Summary
Introduction
Antibacterial pipeline
Key events in antibacterial R&D
Cubist settles patent infringement litigation with Teva over Cubicin
Merck & Co. intends to strengthen antibacterial research through BioRelix
GSK exercises its option with Anacor to commercialize GSK2251052
Zeftera withdrawn following concerns raised by the FDA and the EMA
Durata Therapeutics initiates Phase III trials for dalbavancin
Leading drugs in development
Profiles of key pipeline products
Pipeline forecast to 2016
Competitive landscape
Summary
Introduction
GlaxoSmithKline
Overview
Financial performance
Marketed product portfolio
Research and development
Strategic and growth analysis
Pfizer
Overview
Financial performance
Marketed product portfolio
Research & development
Strategic and growth analysis
Johnson & Johnson
Overview
Financial performance
Marketed product portfolio
Research & development
Strategic and growth analysis
Merck & Co.
Overview
Financial performance
Marketed product portfolio
Research & development
Strategic and growth analysis
Novartis
Overview
Financial performance
Marketed product portfolio
Research & development
Strategic and growth analysis
Appendix
Scope
Market size methodology
Epidemiology
Market forecast
Abbreviations
To order this report:
Drug and Medication Industry: The Antibacterials Market Outlook to 2016
Drug and Medication Business News
More Market Research Report
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas BombourgReportlinkerEmail: [email protected]US: (805)652-2626Intl: +1 805-652-2626
SOURCE Reportlinker
